Navigation Links
Hospira Reports Second-Quarter 2011 Results
Date:7/27/2011

justed financial measures (3)

$
871.5$
453.0$
304.1$
.80GAAP results for the six months ended June 30, 2010 include:(A)

Project Fuel and related charges: $7.7 million reported in Cost of products sold, $5.0 million reported in Restructuring, impairment and (gain) on disposition of assets, net, $0.3 million reported in Research and development and $8.1 million reported in Selling, general and administrative. Project Fuel initiatives include costs for process optimization implementation, severance and other employee benefits, exit costs, and other asset charges. These charges are offset by a $11.4 million gain reported in Restructuring, impairment and (gain) on disposition of assets, net related to the disposal of the non-strategic net assets associated with the Wasserburg, Germany, facility.(B)

Facilities Optimization charges: $4.1 million reported in Cost of products sold and $1.4 million reported in Restructuring, impairment and (gain) on disposition of assets, net. These charges relate to facilities optimization from the closure or departure from certain manufacturing and R&D facilities and include costs for severance and other employee benefits, accelerated depreciation and relocation of production and R&D operations.(C)

Amortization of certain intangible assets reported in Cost of products sold resulting from acquisitions including Mayne Pharma and a generic injectable business by Hospira India.(D)

Certain quality and product related charges reported in Cost of products sold primarily include third party oversight and consulting costs and penalties for failure to supply certain product to customers. These charges are directly associated with Hospira's response to the FDA Warning Letter received in April 2010.(E)

Acquisition and integration-related charges: $2.2 million rep
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Hospira to Host Conference Call for Second-Quarter 2011 Results
2. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
3. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
4. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
5. Hospira Reports First-Quarter 2011 Results
6. Hospira Board Authorizes $1 Billion Share Repurchase Program
7. Hospira to Present at Bank of America / Merrill Lynch 2011 Health Care Conference May 11, 2011
8. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
9. Hospira to Host Conference Call for First-Quarter 2011 Results
10. Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
11. Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... N.J. , July 30, 2015  Medimetriks ... completed the second Phase III clinical study for ... for impetigo.  Medimetriks owns the exclusive U.S. rights ... global trial, conducted at 44 centers with an ... pediatric patients aged 2 months and older with ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... , , Part ... SPRING, Md., Nov. 19 The U.S. Food and ... called the International Internet Week of Action (IIWA), intended ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s ...
... NEWS, Va., Nov. 19 Breast-Specific Gamma Imaging/Molecular Breast ... highly esteemed organizations for the fight against breast cancer: ... College of Surgeons. Both societies published articles supporting the ... early detection of breast cancer. , "These endorsements reinforce ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3
(Date:7/30/2015)... ... 2015 , ... The Mesothelioma Applied Research Foundation (Meso Foundation) ... of 2015’. The bill was introduced in Congress yesterday by Representatives John Katko ... Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill is ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of ... prison system, which has amassed largely enough throughout the years. Florida is the third ... Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning to ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back ... 26, 2015 from 10:00 AM to 2:00 PM local time. On the 26th, ...
(Date:7/30/2015)... ... , ... Bird B Gone, the leader in bird control products for commercial, ... pest birds from the AC units and ventilation systems on hospital roofs. Bird droppings ... West Nile virus. When these droppings dry, the fine powder can be carried into ...
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry eye season, ... that a particularly long, dry and hot 2015 summer season and the dry eye ... advocate Sharon Kleyne will discuss the 2015 summer season and identify the primary dry ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... the nation,s leading,supplier of replacement medical repair parts for ... companies in Ohio by the Case Western,Weatherhead School of ... growth rate exceeding 1000% and has won the award ... clearly one of our region,s most prestigious,honors," said PartsSource ...
... could yield targeted treatments for leukemia, bone marrow transplants ... of all human blood cells has been identified by ... to new treatments for blood cancers and other blood ... progenitor, is the initial offspring of a blood-forming stem ...
... Inc.,(NYSE: BMR ) today announced that its board ... $0.31 per share of common stock. The,dividend is equivalent ... BioMed also announced that its board of directors ... company,s 7.375% Series A Cumulative,Redeemable Preferred Stock for the ...
... WASHINGTON, Dec. 12 Speaker Nancy Pelosi,Majority Leader Steny ... Rahm Emanuel held a news conference late this afternoon ... news conference, President,Bush vetoed the bill. Below are the ... that later today that the President,will veto the SCHIP ...
... experts say recall shouldn,t be health threat , , WEDNESDAY, ... 1.2 million doses of a common childhood vaccine due ... vaccine does not pose a health threat, U.S. health ... recalled two lots of the Haemophilus influenzae ...
... A new school curriculum,that counters abuse of prescription ... a press conference today in Washington, D.C. The,curriculum ... as presentations,for parents. This curriculum was created by ... and expertise of law enforcement,officials; the Pharmaceutical Research ...
Cached Medicine News:Health News:BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 2Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Common Infant Vaccine Recalled 2Health News:Common Infant Vaccine Recalled 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 2Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: